Could a tiny implant curb alcohol cravings? new trial tests Long-Acting naltrexone
NCT ID NCT07333638
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 2 trial tested whether a naltrexone implant, placed under the skin, can help people with alcohol use disorder drink less heavily. 210 adults received either a low-dose, high-dose, or placebo implant, plus counseling. Researchers tracked heavy drinking days over 24 weeks and monitored safety for 48 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
naltrexone implant
What this could lead to
If successful, this could provide a long-acting treatment option to help people with alcohol use disorder reduce heavy drinking.
What could go wrong
This is a Phase 2 trial with a moderate number of participants, so results may not confirm effectiveness or safety. The implant requires a minor surgical procedure, which carries infection or discomfort risks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUD are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The Second Xiangya Hospital of Central South University Address: No. 139, Renmin Road Central, Changsha City
Changsha, Hunan, 410011, China